Akili partners with Shionogi on digital therapeutics in certain Asian markets

7 March 2019

UK-listed PureTech Health (LSE: PRTC) today announced that its independent affiliate Akili has entered into a strategic partnership with Japan’s Shionogi (TYO: 4507) for the commercialization of two of Akili’s digital medicine product candidates, AKL-T01 and AKL-T02, in Japan and Taiwan.

AKL-T01 is currently under review with the US Food and Drug Administration as a potential digital treatment for children with attention-deficit/hyperactivity disorder (ADHD), and AKL-T02 is in late-stage development as a potential digital treatment for cognitive function and related symptoms in children with Autism Spectrum Disorder (ASD).

Financial terms of the collaboration

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK